Small Molecules

04 Nov 2019 Ascentage Pharma and Henlius Form a Combination Therapy Strategic Collaboration
04 Nov 2019 T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease
01 Nov 2019 Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
01 Nov 2019 Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)
01 Nov 2019 Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study
01 Nov 2019 Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®
01 Nov 2019 BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva
01 Nov 2019 RINVOQ™ (upadacitinib) Meets Primary and All Ranked Secondary Endpoints in Phase 3 Study in Psoriatic Arthritis
30 Oct 2019 Cyclerion Therapeutics Announces Praliciguat Topline Phase 2 Results in Diabetic Nephropathy
30 Oct 2019 Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
30 Oct 2019 Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
30 Oct 2019 Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
30 Oct 2019 ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
29 Oct 2019 Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
29 Oct 2019 Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer
29 Oct 2019 Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models
29 Oct 2019 Vapogenix Reports Encouraging Phase II Results of Topical Non-Opioid Pain Medication
29 Oct 2019 Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
29 Oct 2019 Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
29 Oct 2019 Pharmazz submits application for marketing authorization of centhaquine (PMZ-2010), a first-in-class investigational product, for patients with hypovolemic shock
28 Oct 2019 GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
28 Oct 2019 Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors
28 Oct 2019 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma
28 Oct 2019 BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
28 Oct 2019 MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top